Sharp Therapeutics (TSXV:SHRX) Interest Expense: C$-0.23 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
15 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Interest Expense?

Sharp Therapeutics TSXV:SHRX 15 Interest Expense is C$-0.23 Mil as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 15/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sharp Therapeutics's interest expense for the three months ended in Dec. 2025 was C$ -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was C$-0.23 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sharp Therapeutics's Operating Income for the three months ended in Dec. 2025 was C$ -2.37 Mil. Sharp Therapeutics's Interest Expense for the three months ended in Dec. 2025 was C$ -0.06 Mil. Sharp Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sharp Therapeutics  (TSXV:SHRX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sharp Therapeutics's Interest Expense for the three months ended in Dec. 2025 was C$-0.06 Mil. Its Operating Income for the three months ended in Dec. 2025 was C$-2.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was C$1.62 Mil.

Sharp Therapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Sharp Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sharp Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Interest Expense Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Interest Expense
-0.23 -0.24 -0.23

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only -0.10 -0.06 -0.06 -0.06 -0.06
TSXV:SHRX
15GF Score
Sharp Therapeutics Corp TSXV:SHRX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of C$-0.23 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Interest Expense of C$-0.23 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Interest Expense too high?
Sharp Therapeutics' current Interest Expense is C$-0.23 Mil. Overall, Sharp Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Interest Expense compare to VRTX and REGN?
Sharp Therapeutics' Interest Expense of C$-0.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Interest Expense is C$-0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Interest Expense of C$-0.23 Mil. The current Interest Expense is C$-0.23 Mil. Sharp Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Interest Expense is C$-0.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
15GF Score

Get the complete analysis for TSXV:SHRX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price